Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Multiple-Dose, Placebo Controlled Clinical Trial of Two Doses of PP-01 for the Mitigation of Cannabis Withdrawal Symptoms

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Jun 2025 Results presented in the PleoPharma Media Release.
19 Jun 2025 According to a PleoPharma, Inc. media release, the company presented a poster presentation on June 17, 2025 and an oral presentation on June 18, 2025 from this trial at the 2025 annual meeting of The College on Problems of Drug Dependence in New Orleans, LA.
13 Feb 2025 According to a PleoPharma, Inc. media release, the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PP-01 for the mitigation of Cannabis Withdrawal Syndrome in patients with Cannabis Use Disorder.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com